Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

BACKGROUND: The interaction between tumor cells and their immunosuppressive microenvironment promotes tumor progression and drug resistance. Thus, simultaneously targeting tumor cells and stromal cells is expected to have synergistic antitumor effects. Herein, we present for the first time a preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xia, Hou, Pengcong, Chen, Yi, Dai, Yang, Ji, Yinchun, Shen, Yanyan, Su, Yi, Liu, Bo, Wang, Yueliang, Sun, Deqiao, Jiang, Yuchen, Zha, Chuantao, Xie, Zuoquan, Ding, Jian, Geng, Meiyu, Ai, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704710/
https://www.ncbi.nlm.nih.gov/pubmed/31438996
http://dx.doi.org/10.1186/s13046-019-1357-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704710/
https://www.ncbi.nlm.nih.gov/pubmed/31438996
http://dx.doi.org/10.1186/s13046-019-1357-y

Ejemplares similares